US20210355529A1 - Polyphenolic additives in sequencing-by-synthesis - Google Patents
Polyphenolic additives in sequencing-by-synthesis Download PDFInfo
- Publication number
- US20210355529A1 US20210355529A1 US17/386,883 US202117386883A US2021355529A1 US 20210355529 A1 US20210355529 A1 US 20210355529A1 US 202117386883 A US202117386883 A US 202117386883A US 2021355529 A1 US2021355529 A1 US 2021355529A1
- Authority
- US
- United States
- Prior art keywords
- acid
- sequencing
- reagent
- primers
- cleave
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000654 additive Substances 0.000 title abstract description 26
- 238000003786 synthesis reaction Methods 0.000 title abstract description 15
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims abstract description 106
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 67
- 229940074391 gallic acid Drugs 0.000 claims abstract description 51
- 235000004515 gallic acid Nutrition 0.000 claims abstract description 51
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 37
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 34
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 34
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 27
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 51
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims description 44
- 125000003729 nucleotide group Chemical group 0.000 claims description 40
- 239000000243 solution Substances 0.000 claims description 40
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims description 31
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims description 23
- 229960005219 gentisic acid Drugs 0.000 claims description 21
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 18
- -1 pryocatechol Chemical compound 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 16
- 229940079877 pyrogallol Drugs 0.000 claims description 15
- 239000003638 chemical reducing agent Substances 0.000 claims description 14
- 238000012163 sequencing technique Methods 0.000 abstract description 46
- 239000000203 mixture Substances 0.000 abstract description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 13
- 239000003963 antioxidant agent Substances 0.000 abstract description 13
- 238000001308 synthesis method Methods 0.000 abstract description 4
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 26
- 238000009396 hybridization Methods 0.000 description 23
- 229960004337 hydroquinone Drugs 0.000 description 23
- 239000002585 base Substances 0.000 description 21
- 239000013615 primer Substances 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- GOLXRNDWAUTYKT-UHFFFAOYSA-N 3-(1H-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(CCC(=O)O)=CNC2=C1 GOLXRNDWAUTYKT-UHFFFAOYSA-N 0.000 description 14
- 230000000295 complement effect Effects 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 12
- 230000000996 additive effect Effects 0.000 description 11
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 125000005647 linker group Chemical group 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000006227 byproduct Substances 0.000 description 7
- 239000003290 indole 3-propionic acid Substances 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 238000007086 side reaction Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000004020 luminiscence type Methods 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- 241000500125 Cynomorium coccineum Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 3
- 229920002079 Ellagic acid Polymers 0.000 description 3
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical class SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 229960002852 ellagic acid Drugs 0.000 description 3
- 235000004132 ellagic acid Nutrition 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 description 2
- QUXNYZHQBWMPNX-UHFFFAOYSA-N 3-[3,4-Dihydroxy-5-(3,4,5-trihydroxybenzoyloxy)benzoyloxy]-4,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)=C1 QUXNYZHQBWMPNX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000192710 Microcystis aeruginosa Species 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000005620 boronic acid group Chemical group 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- COVFEVWNJUOYRL-UHFFFAOYSA-N dehydrodigallic acid Natural products OC(=O)C1=CC(O)=C(O)C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 COVFEVWNJUOYRL-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 2
- 229920002824 gallotannin Polymers 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- 229920001461 hydrolysable tannin Polymers 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 208000018910 keratinopathic ichthyosis Diseases 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- FBSFWRHWHYMIOG-UHFFFAOYSA-N methyl 3,4,5-trihydroxybenzoate Chemical compound COC(=O)C1=CC(O)=C(O)C(O)=C1 FBSFWRHWHYMIOG-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 150000007965 phenolic acids Chemical class 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- GUEIZVNYDFNHJU-UHFFFAOYSA-N quinizarin Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(O)=CC=C2O GUEIZVNYDFNHJU-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- BRRSNXCXLSVPFC-UHFFFAOYSA-N 2,3,4-Trihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1O BRRSNXCXLSVPFC-UHFFFAOYSA-N 0.000 description 1
- JOELYYRJYYLNRR-UHFFFAOYSA-N 2,3,5-trihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC(O)=C1O JOELYYRJYYLNRR-UHFFFAOYSA-N 0.000 description 1
- IUNJCFABHJZSKB-UHFFFAOYSA-N 2,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C(O)=C1 IUNJCFABHJZSKB-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- SGPUHRSBWMQRAN-UHFFFAOYSA-N 2-[bis(1-carboxyethyl)phosphanyl]propanoic acid Chemical compound OC(=O)C(C)P(C(C)C(O)=O)C(C)C(O)=O SGPUHRSBWMQRAN-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ISPYQTSUDJAMAB-UHFFFAOYSA-N 2-chlorophenol Chemical compound OC1=CC=CC=C1Cl ISPYQTSUDJAMAB-UHFFFAOYSA-N 0.000 description 1
- YVYKOQWMJZXRRM-PUFIMZNGSA-N 3-dehydroshikimate Chemical compound O[C@@H]1C[C@H](C(O)=O)C=C(O)[C@@H]1O YVYKOQWMJZXRRM-PUFIMZNGSA-N 0.000 description 1
- MRBKEAMVRSLQPH-UHFFFAOYSA-N 3-tert-butyl-4-hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1 MRBKEAMVRSLQPH-UHFFFAOYSA-N 0.000 description 1
- 125000001292 4,6-dihydroxy-1,3-phenylene group Chemical group OC1=C(C=C(C(=C1)O)*)* 0.000 description 1
- VZLUGGCFYPMLMI-UHFFFAOYSA-N 5-(3,5-dihydroxyphenyl)benzene-1,3-diol Chemical compound OC1=CC(O)=CC(C=2C=C(O)C=C(O)C=2)=C1 VZLUGGCFYPMLMI-UHFFFAOYSA-N 0.000 description 1
- MGTZCLMLSSAXLD-UHFFFAOYSA-N 5-oxohexanoic acid Chemical compound CC(=O)CCCC(O)=O MGTZCLMLSSAXLD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241001303097 Alchornea cordifolia Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- DJHGAFSJWGLOIV-UHFFFAOYSA-N Arsenic acid Chemical compound O[As](O)(O)=O DJHGAFSJWGLOIV-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- SLWWJZMPHJJOPH-UHFFFAOYSA-N DHS Natural products OC1CC(C(O)=O)=CC(=O)C1O SLWWJZMPHJJOPH-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- UQBOJOOOTLPNST-UHFFFAOYSA-N Dehydroalanine Chemical group NC(=C)C(O)=O UQBOJOOOTLPNST-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical class COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 108030003444 Gallate decarboxylases Proteins 0.000 description 1
- 108030005144 Gallate dioxygenases Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 238000007065 Kolbe-Schmitt synthesis reaction Methods 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241001107128 Myriophyllum Species 0.000 description 1
- 241001244577 Myriophyllum spicatum Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 238000010934 O-alkylation reaction Methods 0.000 description 1
- MTNXHXKXYFWIRI-UHFFFAOYSA-N O=C(O)C1=CC(=O)C(O)C(=O)C1 Chemical compound O=C(O)C1=CC(=O)C(O)C(=O)C1 MTNXHXKXYFWIRI-UHFFFAOYSA-N 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 244000305267 Quercus macrolepis Species 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- 108050008280 Shikimate dehydrogenase Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 150000001336 alkenes Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000005899 aromatization reaction Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229940000488 arsenic acid Drugs 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 150000008109 benzenetriols Chemical class 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical group 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical compound C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 150000005205 dihydroxybenzenes Chemical class 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- OASFYFTVWALXTH-UHFFFAOYSA-L disodium;diphenoxide Chemical compound [Na+].[Na+].[O-]C1=CC=CC=C1.[O-]C1=CC=CC=C1 OASFYFTVWALXTH-UHFFFAOYSA-L 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229920001968 ellagitannin Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000001698 laser desorption ionisation Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- MJGFBOZCAJSGQW-UHFFFAOYSA-N mercury sodium Chemical compound [Na].[Hg] MJGFBOZCAJSGQW-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- IBKQQKPQRYUGBJ-UHFFFAOYSA-N methyl gallate Natural products CC(=O)C1=CC(O)=C(O)C(O)=C1 IBKQQKPQRYUGBJ-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940127285 new chemical entity Drugs 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 1
- 229960001553 phloroglucinol Drugs 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- NEIMTOOWBACOHT-UHFFFAOYSA-N rufigallol Chemical compound O=C1C2=C(O)C(O)=C(O)C=C2C(=O)C2=C1C=C(O)C(O)=C2O NEIMTOOWBACOHT-UHFFFAOYSA-N 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910001023 sodium amalgam Inorganic materials 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6823—Release of bound markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
Definitions
- the invention relates to methods, compositions, devices, systems and kits as described including, without limitation, reagents and mixtures for determining the identity of nucleic acids in nucleotide sequences using, for example, sequencing by synthesis methods.
- the present invention contemplates the use of polyphenolic compounds, known as antioxidant additives, to improve the efficiency of Sequencing-By-Synthesis reactions.
- polyphenolic compounds known as antioxidant additives
- gallic acid (GA) is shown herein to be one of many exemplary SBS polyphenolic additives.
- the invention relates to methods, compositions, devices, systems and kits as described including, without limitation, reagents and mixtures for determining the identity of nucleic acids in nucleotide sequences using, for example, sequencing by synthesis methods.
- the present invention contemplates the use of polyphenolic compounds, known as antioxidant additives, to improve the efficiency of Sequencing-By-Synthesis reactions.
- polyphenolic compounds known as antioxidant additives
- gallic acid (GA) is shown herein to be one of many exemplary SBS polyphenolic additives.
- the present invention contemplates the use polyphenolic compounds as antioxidant additives to the cleave reagent during the cleave step in sequencing by synthesis (SBS).
- SBS sequencing by synthesis
- Such method of application is leads to significant improvement of the sequencing performance (raw error rate thus supporting longer read length).
- Such effect may be due to enhanced efficacy of the cleave reaction via scavenging of radical by-products and deactivation of excess cleave reagent.
- radical by-products may build up in the flow cell leading to carry over into the subsequent extension step thus causing premature de-protection of the 3'-OH moiety and impairing single base incorporation rate.
- the present invention contemplates, in one embodiment, a method of incorporating labeled nucleotides, comprising: a) providing i) a plurality of nucleic acid primers and template molecules, ii) a polymerase, iii) a cleave reagent comprising a reducing agent and a polyphenolic compound, and iv) a plurality of nucleotide analogues wherein at least a portion of said nucleotide analogues is labeled with a label attached through a cleavable linker (e.g.
- a disulfide linker to the base; b) hybridizing at least a portion of said primers to at least a portion of said template molecules so as to create hybridized primers; c) incorporating a first labeled nucleotide analogue with said polymerase into at least a portion of said hybridized primers so as to create extended primers comprising an incorporated labeled nucleotide analogue; d) detecting said incorporated labeled nucleotide analogue; and e) cleaving the cleavable linker of said incorporated nucleotide analogues with said cleave reagent.
- the polyphenolic compound is selected from the group consisting of gallic acid, gentisic acid, pryocatechol, pyrogallol, hydroquinone, and/or resorcinol (or combinations thereof).
- said reducing agent of said cleave reagent comprises TCEP (tris(2-carboxyethyl)phosphine).
- said incorporated nucleotide analogues of step c) further comprise a removable chemical moiety capping the 3'-OH group.
- the cleaving of step e) removes the removable chemical moiety capping the 3'-OH group.
- the method further comprises f) incorporating a second nucleotide analogue with said polymerase into at least a portion of said extended primers.
- said label is fluorescent.
- the present invention also contemplates compositions and reagents.
- the present invention contemplates a cleave reagent comprising i) a reducing agent, and ii) a polyphenolic compound.
- the polyphenolic compound includes, but is not limited to, gallic acid, gentisic acid, pryocatechol, pyrogallol, hydroquinone, and/or resorcinol.
- said reducing agent is TCEP Tris(2-carboxyethyl)phosphine).
- kits where reagents are supplied with instructions for their use.
- the present invention contemplates a kit, comprising: i) the cleave reagent and ii) a plurality of nucleotide analogues wherein at least a portion of said nucleotide analogues is labeled with a label attached through a cleavable linker (e.g. a disulfide linker) to the base.
- a cleavable linker e.g. a disulfide linker
- the cleave reagent comprises i) a reducing agent, and ii) a polyphenolic compound.
- the polyphenolic compound includes, but is not limited to, gallic acid, gentisic acid, pryocatechol, pyrogallol, hydroquinone, and/or resorcinol.
- said reducing agent is TCEP Tris(2-carboxyethyl)phosphine).
- the present invention also contemplates systems, such as systems with flow cells where the flow cells are linked to sources of reagents. See e.g. U.S. Pat. No. 9,145,589, herein incorporated by reference.
- the present invention contemplates a system comprising primers hybridized to template in solution, said solution comprising a cleave reagent, the cleave reagent comprising i) a reducing agent, and ii) a polyphenolic compound.
- the polyphenolic compound includes, but is not limited to, gallic acid, gentisic acid, pryocatechol, pyrogallol, hydroquinone, and/or resorcinol.
- said reducing agent is TCEP Tris(2-carboxyethyl)phosphine).
- said hybridized primers and template are immobilized.
- said hybridized primers and template are in a flow cell.
- linker refers to any molecule (or collection of molecules) capable of attaching a label and/or chemical moiety that is susceptible to cleavage. In one embodiment, cleavage of the linker may produce toxic radical products.
- a linker may include, but is not limited to, a disulfide linker and/or an azide linker.
- Attachment refers to any interaction between a first molecule (e.g., for example, a nucleic acid) and a second molecule (e.g., for example, a label molecule). Attachment may be reversible or irreversible. Such attachment includes, but is not limited to, covalent bonding, ionic bonding, Van der Waals forces or friction, and the like.
- Nucleic acid sequence and “nucleotide sequence” as used herein refer to an oligonucleotide or polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand.
- Such nucleic acids may include, but are not limited to, cDNA, mRNA or other nucleic acid sequences.
- an isolated nucleic acid refers to any nucleic acid molecule that has been removed from its natural state (e.g., removed from a cell and is, in a preferred embodiment, free of other genomic nucleic acid).
- the present invention contemplates hybridizing nucleic acid together. This requires some degree of complementarity.
- complementarity are used in reference to “polynucleotides” and “oligonucleotides” (which are interchangeable terms that refer to a sequence of nucleotides) related by the base-pairing rules. For example, the sequence “C-A-G-T,” is complementary to the sequence “G-T-C-A.”
- Complementarity can be “partial” or “total.” “Partial” complementarity is where one or more nucleic acid bases is not matched according to the base pairing rules.
- Total or “complete” complementarity between nucleic acids is where each and every nucleic acid base is matched with another base under the base pairing rules.
- the degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, as well as detection methods which depend upon binding between nucleic acids.
- nucleotide sequences refer to a degree of complementarity with other nucleotide sequences. There may be partial homology or complete homology (i.e., identity).
- a nucleotide sequence which is partially complementary, i.e., “substantially homologous,” to a nucleic acid sequence is one that at least partially inhibits a completely complementary sequence from hybridizing to a target nucleic acid sequence. The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or Northern blot, solution hybridization and the like) under conditions of low stringency.
- a substantially homologous sequence or probe will compete for and inhibit the binding (i.e., the hybridization) of a completely homologous sequence to a target sequence under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction.
- the absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% identity); in the absence of non-specific binding the probe will not hybridize to the second non-complementary target.
- Low stringency conditions comprise conditions equivalent to binding or hybridization at 42° C. in a solution consisting of 5 x SSPE (43.8 g/l NaCl, 6.9 g/lNaH2PO4 ⁇ H2O and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.1% SDS, 5x Denhardt's reagent ⁇ 50x Denhardt's contains per 500 ml: 5 g Ficoll (Type 400, Pharmacia), 5 g BSA (Fraction V; Sigma) ⁇ and 100 ⁇ g/ml denatured salmon sperm DNA followed by washing in a solution comprising 5x SSPE, 0.1% SDS at 42° C. when a probe of about 500 nucleotides in length. is employed.
- 5 SSPE 43.8 g/l NaCl, 6.9 g/lNaH2PO4 ⁇ H2O and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH
- low stringency conditions may also be employed to comprise low stringency conditions; factors such as the length and nature (DNA, RNA, base composition) of the probe and nature of the target (DNA, RNA, base composition, present in solution or immobilized, etc.) and the concentration of the salts and other components (e.g., the presence or absence of formamide, dextran sulfate, polyethylene glycol), as well as components of the hybridization solution may be varied to generate conditions of low stringency hybridization different from, but equivalent to, the above listed conditions.
- conditions which promote hybridization under conditions of high stringency e.g., increasing the temperature of the hybridization and/or wash steps, the use of formamide in the hybridization solution, etc.
- high stringency e.g., increasing the temperature of the hybridization and/or wash steps, the use of formamide in the hybridization solution, etc.
- hybridization is used in reference to the pairing of complementary nucleic acids using any process by which a strand of nucleic acid joins with a complementary strand through base pairing to form a hybridization complex.
- Hybridization and the strength of hybridization is impacted by such factors as the degree of complementarity between the nucleic acids, stringency of the conditions involved, the Tm of the formed hybrid, and the G:C ratio within the nucleic acids.
- hybridization complex refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bounds between complementary G and C bases and between complementary A and T bases; these hydrogen bonds may be further stabilized by base stacking interactions.
- the two complementary nucleic acid sequences hydrogen bond in an antiparallel configuration.
- a hybridization complex may be formed in solution (e.g., C0 t or R0 t analysis) or between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized to a solid support (e.g., a nylon membrane or a nitrocellulose filter as employed in Southern and Northern blotting, dot blotting or a glass slide as employed in in situ hybridization, including FISH (fluorescent in situ hybridization)).
- a solid support e.g., a nylon membrane or a nitrocellulose filter as employed in Southern and Northern blotting, dot blotting or a glass slide as employed in in situ hybridization, including FISH (fluorescent in situ hybridization)).
- Tm is used in reference to the “melting temperature.”
- the melting temperature is the temperature at which a population of double-stranded nucleic acid molecules becomes half dissociated into single strands.
- stringency is used in reference to the conditions of temperature, ionic strength, and the presence of other compounds such as organic solvents, under which nucleic acid hybridizations are conducted. “Stringency” typically occurs in a range from about Tm to about 20° C. to 25° C. below Tm.
- a “stringent hybridization” can be used to identify or detect identical polynucleotide sequences or to identify or detect similar or related polynucleotide sequences. For example, when fragments are employed in hybridization reactions under stringent conditions the hybridization of fragments which contain unique sequences (i.e., regions which are either non-homologous to or which contain less than about 50% homology or complementarity) are favored.
- conditions of “weak” or “low” stringency may occur with nucleic acids that are derived from organisms that are genetically diverse (i.e., for example, the frequency of complementary sequences is usually low between such organisms).
- amplifiable nucleic acid is used in reference to nucleic acids which may be amplified by any amplification method. It is contemplated that “amplifiable nucleic acid” will usually comprise “sample template.”
- sample template or (more simply) “template” refers to nucleic acid originating from a sample which is analyzed for the presence of a target sequence of interest.
- background template is used in reference to nucleic acid other than sample template which may or may not be present in a sample. Background template is most often inadvertent. It may be the result of carryover, or it may be due to the presence of nucleic acid contaminants sought to be purified away from the sample. For example, nucleic acids from organisms other than those to be detected may be present as background in a test sample.
- Amplification is defined as the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction. Dieffenbach C. W. and G. S. Dveksler (1995) In: PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview, N.Y.
- PCR polymerase chain reaction
- the desired amplified segments of the target sequence become the predominant sequences (in terms of concentration) in the mixture, they are said to be “PCR amplified”.
- PCR it is possible to amplify a single copy of a specific target sequence in genomic DNA to a level detectable by several different methodologies (e.g., hybridization with a labeled probe; incorporation of biotinylated primers followed by avidin-enzyme conjugate detection; incorporation of 32P-labeled deoxynucleotide triphosphates, such as dCTP or dATP, into the amplified segment).
- any oligonucleotide sequence can be amplified with the appropriate set of primer molecules.
- the amplified segments created by the PCR process itself are, themselves, efficient templates for subsequent PCR amplifications.
- the term “primer” refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product which is complementary to a nucleic acid strand is induced, (i.e., in the presence of nucleotides and an inducing agent such as DNA polymerase and at a suitable temperature and pH).
- the primer is preferably single stranded for maximum efficiency in amplification, but may alternatively be double stranded. If double stranded, the primer is first treated to separate its strands before being used to prepare extension products.
- the primer is an oligodeoxy-ribonucleotide.
- the primer must be sufficiently long to prime the synthesis of extension products in the presence of the inducing agent. The exact lengths of the primers will depend on many factors, including temperature, source of primer and the use of the method.
- probe refers; to an oligonucleotide (i.e., a sequence of nucleotides), whether occurring naturally as in a purified restriction digest or produced synthetically, recombinantly or by PCR amplification, which is capable of hybridizing to another oligonucleotide of interest.
- a probe may be single-stranded or double-stranded. Probes are useful in the detection, identification and isolation of particular gene sequences.
- any probe used in the present invention will be labeled with any “reporter molecule,” so that is detectable in any detection system, including, but not limited to enzyme (e.g., ELISA, as well as enzyme-based histochemical assays), fluorescent, radioactive, and luminescent systems. It is not intended that the present invention be limited to any particular detection system or label.
- label or “detectable label” are used herein, to refer to any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means.
- labels include biotin for staining with labeled streptavidin conjugate, magnetic beads (e.g., Dynabeads®), fluorescent dyes (e.g., fluorescein, texas red, rhodamine, green fluorescent protein, and the like), radiolabels (e.g., 3H, 125I, 35S, 14C, or 32P), enzymes (e.g., horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and calorimetric labels such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads.
- fluorescent dyes e.g., fluorescein, texas red, rhodamine, green fluorescent protein, and the
- Patents teaching the use of such labels include, but are not limited to, U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241 (all herein incorporated by reference).
- the label is typically fluorescent and is linked to the base of the nucleotide.
- the attachment is usually to the 5-position.
- a deaza derivative is created and the label is linked to a 7-position of deaza-adenine or deaza-guanine.
- the labels contemplated in the present invention may be detected by many methods.
- radiolabels may be detected using photographic film or scintillation counters
- fluorescent markers may be detected using a photodetector to detect emitted light.
- Enzymatic labels are typically detected by providing the enzyme with a substrate and detecting, the reaction product produced by the action of the enzyme on the substrate, and calorimetric labels are detected by simply visualizing the colored label.
- Luminescence and/or fluorescence refers to any process of emitting electromagnetic radiation (light) from an object, chemical and/or compound. Luminescence and/or fluorescence results from a system which is “relaxing” from an excited state to a lower state with a corresponding release of energy in the form of a photon. These states can be electronic, vibronic, rotational, or any combination of the three. The transition responsible for luminescence can be stimulated through the release of energy stored in the system chemically or added to the system from an external source.
- the external source of energy can be of a variety of types including, but not limited to, chemical, thermal, electrical, magnetic, electromagnetic, physical or any other type capable of causing a system to be excited into a state higher than the ground state.
- a system can be excited by absorbing a photon of light, by being placed in an electrical field, or through a chemical oxidation-reduction reaction.
- the energy of the photons emitted during luminescence can be in a range from low-energy microwave radiation to high-energy x-ray radiation.
- luminescence refers to photons in the range from UV to IR radiation.
- FIG. 1 presents exemplary data showing a comparison of sequencing performance for runs containing gallic acid (addG) in Cleave solution vs Baseline runs.
- Sequencing parameters include average error rate, average percentage of perfect (error free) reads, phasing parameters (lead and lag).
- FIG. 2 presents exemplary data showing a comparison of sequencing performance for runs containing gallic acid (addG) in Cleave solution vs Baseline runs. Sequencing included assessment of called variants (true positives—TP, false positives—FP).
- FIG. 3 presents exemplary data showing a comparison of sequencing performance for runs containing gallic acid (addG) in Cleave solution vs Baseline runs. Sequencing included assessment of average error rate per cycle.
- additiveG gallic acid
- FIG. 4 presents exemplary data showing a comparison of sequencing performance for runs containing gallic acid (addG) in Cleave solution vs Baseline runs. Sequencing included assessment of the following performance indicators: average error rate per cycle, average percentage of perfect reads, percent of signal retention, false positive rate and lead/lag. Values higher than 0.95 on the third bar indicate statistical significance, first bar corresponds to baseline, second to experiment with relative improvement factor.
- additiveG gallic acid
- FIG. 5 presents exemplary data showing an LC-MS analysis of a cleaved spacer arm terminating with free SH group and exposure to Cleave without additives. Formation of alkene moiety detected as a result of side reactions during cleavage step.
- FIG. 6 presents exemplary data showing a comparison of sequencing performance for runs containing gallic acid (addG) in Cleave solution vs solutions with gallic acid and Tween detergent. Sequencing included assessment of the following performance indicators: average error rate per cycle, average percentage of perfect reads, percent of signal retention, false positive rate and lead/lag. Values higher than 0.95 on the third bar indicate statistical significance, first bar corresponds to baseline, second to experiment with relative improvement factor
- FIG. 7 presents exemplary data showing a comparison of sequencing performance for runs containing addG alternatives in Cleave solution (pyrogallol, pyrocatechol, gentisic acid) vs baseline runs without any additive. Results are provided for two sample types (Clones and Gene Panel). Improvements are noted for sequencing KPIs such as error rate, percent perfect and lead/lag when addG alternatives such as pyrogallol, pyrocatechol, gentisic acid are added to Cleave.
- FIG. 8 presents representative electropherograms of sequencing products after sequencing under baseline conditions (A) and with gallic acid additive in Cleave (B). Higher yield of full length product observed in case with additive (B).
- FIG. 9 presents exemplary RP-HPLC cleavage studies of labeled dCTP nucleotide in the absence (baseline) and presence of additive (examples of gallic and gentisic acid). Byproducts are clearly visible in baseline and absent in chromatograms with additives.
- FIG. 10 presents exemplary data showing a comparison of sequencing performance for runs containing baseline imaging buffer vs imaging buffer containing additives: GR 5.10: Replace baseline Imaging buffer with a single HEPES pH 7.5 buffer with Gentisic acid at final concentration of 25 mM; GR 5.4: Add Gentisic acid (25 mM) to Image B; GR 5.5: Image B buffer with Trolox removed and Gentisic acid added (25 mM).
- FIG. 11 presents exemplary data showing the relative bead loss in flow cells during runs comparing indole-3-propionic acid (IPA: AddC_15FC) and gallic acid (GA: AddG_7FC).
- IPA indole-3-propionic acid
- GA gallic acid
- FIG. 12 presents exemplary data comparing the raw error rate for ascorbic acid (Add AA), additive C (Add C), additive G (light) along with an additive-free control (No add) where the results were generated in a sequencing run using the NA12878/101X gene panel as template.
- the raw error rate for ascorbic acid is significantly better than i) the no additive run, and ii) the run with additive C (while performing comparably to additive G).
- the invention relates to methods, compositions, devices, systems and kits as described including, without limitation, reagents and mixtures for determining the identity of nucleic acids in nucleotide sequences using, for example, sequencing by synthesis methods.
- the present invention contemplates the use of polyphenolic compounds, known as antioxidant additives, to improve the efficiency of Sequencing-By-Synthesis reactions.
- polyphenolic compounds known as antioxidant additives
- gallic acid (GA) is shown herein to be one of many exemplary SBS polyphenolic additives.
- One step in the sequencing-by-synthesis workflow is the removal of the fluorescent label which is covalently attached via a cleavable linker molecule to the ring-position of the heterocyclic base of the nucleotide (reversible terminator) involved in the incorporation step.
- the efficacy of the cleave step is reflected not only in the efficiency of the fluorescent label cleavage but also in the mitigation of reaction by-products that could accumulate in the flow cell and interfere with subsequent base incorporation step. Examples of such compounds are radical by-products that may form due to radical pathways involved in the omolytic scission of the linker molecule to release the fluorescent label and excess cleave reagent (i.
- TCEP tris(2-carboxyethyl)phosphine
- the present invention contemplates a series of method steps performed by an automated sequencing by synthesis instrument. See U.S. Pat. No. 9,145,589, hereby incorporated by reference.
- the instrument is comprised of numerous reagent reservoirs. Each reagent reservoir has a specific reactivity reagent dispensed within the reservoir to support the SBS process, for example:
- One reactive step in a method for sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators comprises cleaving a fluorescent label from a nucleotide analogue molecule. It is not intended that the present invention be limited by the nature of the cleaving agent.
- the SBS method comprises doing different steps at different stations.
- each station is associated with a particular step. While not limited to particular formulations, some examples for these steps and the associated reagents are shown below:
- composition of Extend A is as follows:
- the present invention contemplates compositions and compounds that are polyphenolic compounds as antioxidant additives which improve methods of sequencing by synthesis.
- the polyphenolic compound includes, but is not limited to, gallic acid, gentisic acid, pryocatechol, pyrogallol, hydroquinone, and/or resorcinol.
- One embodiment of the invention includes addition of polyphenolic additives in sequencing reactions of Cleavage solution to improve lifetime of solution, to reduce undesirable free radical driven side reactions, allow premixing, and as a result improve sequencing performance.
- Another embodiment includes addition of polyphenolic compounds to Imaging solution to improve lifetime of solution and to reduce undesirable free radical driven side reactions.
- Yet another embodiment of the invention is addition of polyphenolic compounds to Extend solution to improve lifetime of solution and to reduce undesirable free radical driven side reactions.
- the polyphenolic compounds are antioxidants.
- the polyphenolic compounds have free radical scavenging properties.
- One Imaging solution currently used on GeneReader uses an active oxygen scavenging system and radical/triplet state scavenger. Extend A/B solutions do not contain reducing agents due to compatibility with sequencing chemistry (disufide bridges).
- polyphenolic anti-oxidant compounds are identified that actively scavenge dissolved oxygen out of a Cleave solution and prolong useful life time of a Cleave solution and increase its efficiency.
- improved performance of a Cleave step and reduction of side reactions is disclosed.
- G Gallic acid
- Gallic acid is found in a number of land plants, such as the parasitic plant, Cynomorium coccineum, the aquatic plant, Myriophyllum spicatum, and the blue-green alga, Microcystis aeruginosa. Zucca et al., “Evaluation of Antioxidant Potential of “Maltese Mushroom” (Cynomorium coccineum) by Means of Multiple Chemical and Biological Assays” Nutrients 5(1):149-161; and Nakai, S (2000). “Myriophyllum spicatum-released allelopathic polyphenols inhibiting growth of blue-green algae Microcystis aeruginosa” Water Research 34(11):3026-3032.
- Gallic acid is a trihydroxybenzoic acid, a type of phenolic acid, a type of organic acid, also known as 3,4,5-trihydroxybenzoic acid, found in gallnuts, sumac, witch hazel, tea leaves, oak bark, and other plants.
- the chemical formula is C 6 H 2 (OH) 3 COOH, having the following structure:
- Gallic acid is found both free and as part of hydrolyzable tannins.
- the gallic acid groups are usually bonded to form dimers such as ellagic acid.
- Hydrolysable tannins break down on hydrolysis to give gallic acid and glucose or ellagic acid and glucose, known as gallotannins and ellagitannins respectively.
- Gallic acid may also form intermolecular esters (depsides) such as digallic and trigallic acid, and cyclic ether-esters (depsidones) and is commonly used in the pharmaceutical industry.
- depsides intermolecular esters
- depsidones cyclic ether-esters
- Gallic acid is formed from 3-dehydroshikimate by the action of the enzyme shikimate dehydrogenase to produce 3,5-didehydroshikimate. This latter compound tautomerizes to form the redox equivalent gallic acid, where the equilibrium lies essentially entirely toward gallic acid because of the coincidentally occurring aromatization. Dewick et al., (1969) “Phenol biosynthesis in higher plants. Gallic acid”. Biochemical Journal 113 (3): 537-542. Gallate dioxygenase and gallate decarboxylase are enzymes responsible for the degradation of gallic acid.
- the present invention contemplates an SBS reagent (e.g., for example, a Cleave 1 buffer, where gallic acid is not mixed in the absence of TCEP.
- an SBS reagent e.g., for example, a Cleave 1 buffer, where gallic acid is not mixed in the absence of TCEP.
- gallic acid and TCEP are both present in the SBS reagent, no bead loss is observed.
- Gentisic acid is a dihydroxybenzoic acid. It is a derivative of benzoic acid and a minor (1%) product of the metabolic break down of aspirin. It is also found in the African tree Alchornea cordifolia and in wine.
- Gentisic acid may be produced by carboxylation of hydroquinone:
- the compound can be synthesized from Salicylic acid via Elbs persulfate oxidation (50% yield). Schock Jr. et al., (1951) “The Persulfate Oxidation of Salicylic Acid. 2,3,5-Trihydroxybenzoic Acid” The Journal of Organic Chemistry 16(11):1772-1775.
- gentisic acid is readily oxidized and is used as an antioxidant excipient in some pharmaceutical preparations. In the laboratory, it is used as a sample matrix in matrix-assisted laser desorption/ionization (MALDI) mass spectrometry, and has been shown to conveniently detect peptides incorporating the boronic acid moiety by MALDI.
- MALDI matrix-assisted laser desorption/ionization
- Pyrocatechol also known as catechol or 1,2-dihydroxybenzene, is an organic compound with the molecular formula C 6 H 4 (OH)2. It is the ortho isomer of the three isomeric benzenediols. This colorless compound occurs naturally in trace amounts. It was first discovered by destructive distillation of the plant extract catechin. About 20 million kg are now synthetically produced annually as a commodity organic chemical, mainly as a precursor to pesticides, flavors, and fragrances.
- Catechol is produced industrially by the hydroxylation of phenol using hydrogen peroxide:
- Pyrogallol is an organic compound with the formula C 6 H 3 (OH) 3 having the following chemical structure:
- Hydroquinone also benzene-1,4-diol or quinol, is an aromatic organic compound that is a type of phenol, a derivative of benzene, having the chemical formula C6H4(OH)2, having the following structure:
- hydroquinone's O—H groups resembles other phenols, being weakly acidic.
- the resulting conjugate base undergoes easy O-alkylation to give mono- and diethers.
- hydroquinone is highly susceptible to ring substitution by Friedel-Crafts reactions such as alkylation. This reaction is exploited en route to popular antioxidants such as 2-tert-butyl-4-methoxyphenol (“BHA”).
- BHA 2-tert-butyl-4-methoxyphenol
- the useful dye quinizarin is produced by diacylation of hydroquinone with phthalic anhydride.
- Hydroquinone undergoes oxidation under mild conditions to give benzoquinone. This process can be reversed.
- Some naturally occurring hydroquinone derivatives exhibit this sort of reactivity, one example being coenzyme Q. Industrially this reaction is exploited both with hydroquinone itself but more often with its derivatives where one OH has been replaced by an amine.
- hydroquinone prevents polymerization of acrylic acid, methyl methacrylate, cyanoacrylate, and other monomers that are susceptible to radical-initiated polymerization. This application exploits the antioxidant properties of hydroquinone.
- Hydroquinone can undergo mild oxidation to convert to the compound parabenzoquinone, C6H4O2, often called p-quinone or simply quinone. Reduction of quinone reverses this reaction back to hydroquinone.
- Some biochemical compounds in nature have this sort of hydroquinone or quinone section in their structures, such as Coenzyme Q, and can undergo similar redox interconversions.
- Hydroquinone can lose an H+ from both to form a diphenolate ion.
- the disodium diphenolate salt of hydroquinone is used as an alternating comonomer unit in the production of the polymer PEEK.
- Resorcinal is the 1,3-isomer (or meta-isomer) of benzenediol with the formula C 6 H 4 (OH) 2 , having the following structure:
- Resorcinol crystallizes from benzene as colorless needles that are readily soluble in water, alcohol, and ether, but insoluble in chloroform and carbon disulfide. Sodium amalgam reduces it to dihydroresorcin, which when heated to 150 to 160° C. with concentrated barium hydroxide solution gives ⁇ -acetylbutyric acid and when fused with potassium hydroxide, resorcinol yields phloroglucin, pyrocatechol, and diresorcin.
- the present invention contemplates a SBS method comprising the steps shown in Table 1. See Olejink et al., “Methods And Compositions For Inhibiting Undesired Cleaving Of Labels” U.S. Pat. No. 8,623,598 (herein incorporated by reference in its entirety).
- Dispense Reagent Reagent 1 100 67 3 65 7 2. Incubate Reagent Reagent 1 n/a n/a 3 65 210 3. Dispense Reagent Reagent 2 100 67 4 65 7 4. Incubate Reagent Reagent 2 n/a n/a 4 65 210 5. Dispense Reagent Reagent 3 330 27 5 Ambient 12 6. Dispense Reagent Reagent 200 27 5 Ambient 15 4 + 5 7. Image n/a n/a n/a 11 Ambient 210 8.
- Dispense Reagent Reagent 3 330 27 20 65 12 9.
Abstract
Description
- This application is a continuation of U.S. application Ser. No. 16/422,056, filed May 24, 20919, which is a continuation of U.S. application Ser. No. 15/427,664, filed Feb. 08, 2017, (now U.S. Pat. No. 10,337,050), which claims priority to, and the benefit of, U.S. provisional application Nos. 62/293,969, filed Feb. 11, 2016 and 62/419,685 filed Nov. 09, 2016, under 35 USC § 119(e). The contents of each of these applications are hereby incorporated by reference in their entireties.
- The invention relates to methods, compositions, devices, systems and kits as described including, without limitation, reagents and mixtures for determining the identity of nucleic acids in nucleotide sequences using, for example, sequencing by synthesis methods. In particular, the present invention contemplates the use of polyphenolic compounds, known as antioxidant additives, to improve the efficiency of Sequencing-By-Synthesis reactions. For example, gallic acid (GA) is shown herein to be one of many exemplary SBS polyphenolic additives.
- Over the past 25 years, the amount of DNA sequence information that has been generated and deposited into Genbank has grown exponentially. Traditional sequencing methods (e.g., for example Sanger sequencing) are being replaced by next-generation sequencing technologies that use a form of sequencing by synthesis (SBS), wherein specially designed nucleotides and DNA polymerases are used to read the sequence of chip-bound, single-stranded DNA templates in a controlled manner. To attain high throughput, many millions of such template spots are arrayed across a sequencing chip and their sequence is independently read out and recorded.
- Systems for using arrays for DNA sequencing are known (e.g., Ju et al., U.S. Pat. No. 6,664,079). However, there is a continued need for methods and compositions for increasing the accuracy and/or efficiency of sequencing nucleic acid sequences and increasing the read lengths available for automated sequencing.
- The invention relates to methods, compositions, devices, systems and kits as described including, without limitation, reagents and mixtures for determining the identity of nucleic acids in nucleotide sequences using, for example, sequencing by synthesis methods. In particular, the present invention contemplates the use of polyphenolic compounds, known as antioxidant additives, to improve the efficiency of Sequencing-By-Synthesis reactions. For example, gallic acid (GA) is shown herein to be one of many exemplary SBS polyphenolic additives.
- In one embodiment, the present invention contemplates the use polyphenolic compounds as antioxidant additives to the cleave reagent during the cleave step in sequencing by synthesis (SBS). Such method of application is leads to significant improvement of the sequencing performance (raw error rate thus supporting longer read length). Such effect may be due to enhanced efficacy of the cleave reaction via scavenging of radical by-products and deactivation of excess cleave reagent. Such radical by-products may build up in the flow cell leading to carry over into the subsequent extension step thus causing premature de-protection of the 3'-OH moiety and impairing single base incorporation rate.
- The present invention contemplates, in one embodiment, a method of incorporating labeled nucleotides, comprising: a) providing i) a plurality of nucleic acid primers and template molecules, ii) a polymerase, iii) a cleave reagent comprising a reducing agent and a polyphenolic compound, and iv) a plurality of nucleotide analogues wherein at least a portion of said nucleotide analogues is labeled with a label attached through a cleavable linker (e.g. a disulfide linker) to the base; b) hybridizing at least a portion of said primers to at least a portion of said template molecules so as to create hybridized primers; c) incorporating a first labeled nucleotide analogue with said polymerase into at least a portion of said hybridized primers so as to create extended primers comprising an incorporated labeled nucleotide analogue; d) detecting said incorporated labeled nucleotide analogue; and e) cleaving the cleavable linker of said incorporated nucleotide analogues with said cleave reagent. In one embodiment, the polyphenolic compound is selected from the group consisting of gallic acid, gentisic acid, pryocatechol, pyrogallol, hydroquinone, and/or resorcinol (or combinations thereof). In one embodiment, said reducing agent of said cleave reagent comprises TCEP (tris(2-carboxyethyl)phosphine). In one embodiment, said incorporated nucleotide analogues of step c) further comprise a removable chemical moiety capping the 3'-OH group. In one embodiment, the cleaving of step e) removes the removable chemical moiety capping the 3'-OH group. In one embodiment, the method further comprises f) incorporating a second nucleotide analogue with said polymerase into at least a portion of said extended primers.
- It is not intended that the present invention be limited to the type of label. A variety of labels are contemplated. In a preferred embodiment, said label is fluorescent.
- The present invention also contemplates compositions and reagents. In one embodiment, the present invention contemplates a cleave reagent comprising i) a reducing agent, and ii) a polyphenolic compound. In one embodiment, the polyphenolic compound includes, but is not limited to, gallic acid, gentisic acid, pryocatechol, pyrogallol, hydroquinone, and/or resorcinol. In one embodiment, said reducing agent is TCEP Tris(2-carboxyethyl)phosphine).
- The present invention also contemplates kits, where reagents are supplied with instructions for their use. In one embodiment, the present invention contemplates a kit, comprising: i) the cleave reagent and ii) a plurality of nucleotide analogues wherein at least a portion of said nucleotide analogues is labeled with a label attached through a cleavable linker (e.g. a disulfide linker) to the base. In one embodiment, the cleave reagent comprises i) a reducing agent, and ii) a polyphenolic compound. In one embodiment, the polyphenolic compound includes, but is not limited to, gallic acid, gentisic acid, pryocatechol, pyrogallol, hydroquinone, and/or resorcinol. In one embodiment, said reducing agent is TCEP Tris(2-carboxyethyl)phosphine).
- The present invention also contemplates systems, such as systems with flow cells where the flow cells are linked to sources of reagents. See e.g. U.S. Pat. No. 9,145,589, herein incorporated by reference. In one embodiment, the present invention contemplates a system comprising primers hybridized to template in solution, said solution comprising a cleave reagent, the cleave reagent comprising i) a reducing agent, and ii) a polyphenolic compound. In one embodiment, the polyphenolic compound includes, but is not limited to, gallic acid, gentisic acid, pryocatechol, pyrogallol, hydroquinone, and/or resorcinol. In one embodiment, said reducing agent is TCEP Tris(2-carboxyethyl)phosphine). In one embodiment, said hybridized primers and template are immobilized. In one embodiment, said hybridized primers and template are in a flow cell.
- To facilitate the understanding of this invention, a number of terms are defined below. Terms defined herein have meanings as commonly understood by a person of ordinary skill in the areas relevant to the present invention. Terms such as “a”, “an” and “the” are not intended to refer to only a singular entity but also plural entities and also includes the general class of which a specific example may be used for illustration. The terminology herein is used to describe specific embodiments of the invention, but their usage does not delimit the invention, except as outlined in the claims.
- The term “about” as used herein, in the context of any of any assay measurements refers to +/− 5% of a given measurement.
- The term “linker” as used herein, refers to any molecule (or collection of molecules) capable of attaching a label and/or chemical moiety that is susceptible to cleavage. In one embodiment, cleavage of the linker may produce toxic radical products. For example, a linker may include, but is not limited to, a disulfide linker and/or an azide linker.
- The term “attached” as used herein, refers to any interaction between a first molecule (e.g., for example, a nucleic acid) and a second molecule (e.g., for example, a label molecule). Attachment may be reversible or irreversible. Such attachment includes, but is not limited to, covalent bonding, ionic bonding, Van der Waals forces or friction, and the like.
- “Nucleic acid sequence” and “nucleotide sequence” as used herein refer to an oligonucleotide or polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand. Such nucleic acids may include, but are not limited to, cDNA, mRNA or other nucleic acid sequences.
- The term “an isolated nucleic acid”, as used herein, refers to any nucleic acid molecule that has been removed from its natural state (e.g., removed from a cell and is, in a preferred embodiment, free of other genomic nucleic acid).
- In some embodiments, the present invention contemplates hybridizing nucleic acid together. This requires some degree of complementarity. As used herein, the terms “complementary” or “complementarity” are used in reference to “polynucleotides” and “oligonucleotides” (which are interchangeable terms that refer to a sequence of nucleotides) related by the base-pairing rules. For example, the sequence “C-A-G-T,” is complementary to the sequence “G-T-C-A.” Complementarity can be “partial” or “total.” “Partial” complementarity is where one or more nucleic acid bases is not matched according to the base pairing rules. “Total” or “complete” complementarity between nucleic acids is where each and every nucleic acid base is matched with another base under the base pairing rules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, as well as detection methods which depend upon binding between nucleic acids.
- The terms “homology” and “homologous” as used herein in reference to nucleotide sequences refer to a degree of complementarity with other nucleotide sequences. There may be partial homology or complete homology (i.e., identity). A nucleotide sequence which is partially complementary, i.e., “substantially homologous,” to a nucleic acid sequence is one that at least partially inhibits a completely complementary sequence from hybridizing to a target nucleic acid sequence. The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or Northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or probe will compete for and inhibit the binding (i.e., the hybridization) of a completely homologous sequence to a target sequence under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% identity); in the absence of non-specific binding the probe will not hybridize to the second non-complementary target.
- Low stringency conditions comprise conditions equivalent to binding or hybridization at 42° C. in a solution consisting of 5 x SSPE (43.8 g/l NaCl, 6.9 g/lNaH2PO4·H2O and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.1% SDS, 5x Denhardt's reagent {50x Denhardt's contains per 500 ml: 5 g Ficoll (Type 400, Pharmacia), 5 g BSA (Fraction V; Sigma)} and 100 μg/ml denatured salmon sperm DNA followed by washing in a solution comprising 5x SSPE, 0.1% SDS at 42° C. when a probe of about 500 nucleotides in length. is employed. Numerous equivalent conditions may also be employed to comprise low stringency conditions; factors such as the length and nature (DNA, RNA, base composition) of the probe and nature of the target (DNA, RNA, base composition, present in solution or immobilized, etc.) and the concentration of the salts and other components (e.g., the presence or absence of formamide, dextran sulfate, polyethylene glycol), as well as components of the hybridization solution may be varied to generate conditions of low stringency hybridization different from, but equivalent to, the above listed conditions. In addition, conditions which promote hybridization under conditions of high stringency (e.g., increasing the temperature of the hybridization and/or wash steps, the use of formamide in the hybridization solution, etc.) may also be used.
- As used herein, the term “hybridization” is used in reference to the pairing of complementary nucleic acids using any process by which a strand of nucleic acid joins with a complementary strand through base pairing to form a hybridization complex. Hybridization and the strength of hybridization (i.e., the strength of the association between the nucleic acids) is impacted by such factors as the degree of complementarity between the nucleic acids, stringency of the conditions involved, the Tm of the formed hybrid, and the G:C ratio within the nucleic acids.
- As used herein the term “hybridization complex” refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bounds between complementary G and C bases and between complementary A and T bases; these hydrogen bonds may be further stabilized by base stacking interactions. The two complementary nucleic acid sequences hydrogen bond in an antiparallel configuration. A hybridization complex may be formed in solution (e.g., C0 t or R0 t analysis) or between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized to a solid support (e.g., a nylon membrane or a nitrocellulose filter as employed in Southern and Northern blotting, dot blotting or a glass slide as employed in in situ hybridization, including FISH (fluorescent in situ hybridization)).
- As used herein, the term “Tm ” is used in reference to the “melting temperature.” The melting temperature is the temperature at which a population of double-stranded nucleic acid molecules becomes half dissociated into single strands. As indicated by standard references, a simple estimate of the Tm value may be calculated by the equation: Tm=81.5+0.41 (% G+C), when a nucleic acid is in aqueous solution at 1M NaCl. Anderson et al., “Quantitative Filter Hybridization” In: Nucleic Acid Hybridization (1985). More sophisticated computations take structural, as well as sequence characteristics, into account for the calculation of Tm.
- As used herein the term “stringency” is used in reference to the conditions of temperature, ionic strength, and the presence of other compounds such as organic solvents, under which nucleic acid hybridizations are conducted. “Stringency” typically occurs in a range from about Tm to about 20° C. to 25° C. below Tm. A “stringent hybridization” can be used to identify or detect identical polynucleotide sequences or to identify or detect similar or related polynucleotide sequences. For example, when fragments are employed in hybridization reactions under stringent conditions the hybridization of fragments which contain unique sequences (i.e., regions which are either non-homologous to or which contain less than about 50% homology or complementarity) are favored. Alternatively, when conditions of “weak” or “low” stringency are used hybridization may occur with nucleic acids that are derived from organisms that are genetically diverse (i.e., for example, the frequency of complementary sequences is usually low between such organisms).
- As used herein, the term “amplifiable nucleic acid” is used in reference to nucleic acids which may be amplified by any amplification method. It is contemplated that “amplifiable nucleic acid” will usually comprise “sample template.”
- As used herein, the term “sample template” or (more simply) “template” refers to nucleic acid originating from a sample which is analyzed for the presence of a target sequence of interest. In contrast, “background template” is used in reference to nucleic acid other than sample template which may or may not be present in a sample. Background template is most often inadvertent. It may be the result of carryover, or it may be due to the presence of nucleic acid contaminants sought to be purified away from the sample. For example, nucleic acids from organisms other than those to be detected may be present as background in a test sample.
- “Amplification” is defined as the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction. Dieffenbach C. W. and G. S. Dveksler (1995) In: PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview, N.Y.
- As used herein, the term “polymerase chain reaction” (“PCR”) refers to the method of K. B. Mullis U.S. Pat. Nos. 4,683,195 and 4,683,202, herein incorporated by reference, which describe a method for increasing the concentration of a segment of a target sequence in a mixture of genomic DNA without cloning or purification. The length of the amplified segment of the desired target sequence is determined by the relative positions of two oligonucleotide primers with respect to each other, and therefore, this length is a controllable parameter. By virtue of the repeating aspect of the process, the method is referred to as the “polymerase chain reaction” (hereinafter “PCR”). Because the desired amplified segments of the target sequence become the predominant sequences (in terms of concentration) in the mixture, they are said to be “PCR amplified”. With PCR, it is possible to amplify a single copy of a specific target sequence in genomic DNA to a level detectable by several different methodologies (e.g., hybridization with a labeled probe; incorporation of biotinylated primers followed by avidin-enzyme conjugate detection; incorporation of 32P-labeled deoxynucleotide triphosphates, such as dCTP or dATP, into the amplified segment). In addition to genomic DNA, any oligonucleotide sequence can be amplified with the appropriate set of primer molecules. In particular, the amplified segments created by the PCR process itself are, themselves, efficient templates for subsequent PCR amplifications.
- As used herein, the term “primer” refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product which is complementary to a nucleic acid strand is induced, (i.e., in the presence of nucleotides and an inducing agent such as DNA polymerase and at a suitable temperature and pH). The primer is preferably single stranded for maximum efficiency in amplification, but may alternatively be double stranded. If double stranded, the primer is first treated to separate its strands before being used to prepare extension products. Preferably, the primer is an oligodeoxy-ribonucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the inducing agent. The exact lengths of the primers will depend on many factors, including temperature, source of primer and the use of the method.
- As used herein, the term “probe” refers; to an oligonucleotide (i.e., a sequence of nucleotides), whether occurring naturally as in a purified restriction digest or produced synthetically, recombinantly or by PCR amplification, which is capable of hybridizing to another oligonucleotide of interest. A probe may be single-stranded or double-stranded. Probes are useful in the detection, identification and isolation of particular gene sequences. It is contemplated that any probe used in the present invention will be labeled with any “reporter molecule,” so that is detectable in any detection system, including, but not limited to enzyme (e.g., ELISA, as well as enzyme-based histochemical assays), fluorescent, radioactive, and luminescent systems. It is not intended that the present invention be limited to any particular detection system or label.
- The term “label” or “detectable label” are used herein, to refer to any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Such labels include biotin for staining with labeled streptavidin conjugate, magnetic beads (e.g., Dynabeads®), fluorescent dyes (e.g., fluorescein, texas red, rhodamine, green fluorescent protein, and the like), radiolabels (e.g., 3H, 125I, 35S, 14C, or 32P), enzymes (e.g., horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and calorimetric labels such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads. Patents teaching the use of such labels include, but are not limited to, U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241 (all herein incorporated by reference).
- In a preferred embodiment, the label is typically fluorescent and is linked to the base of the nucleotide. For cytosine and thymine, the attachment is usually to the 5-position. For the other bases, a deaza derivative is created and the label is linked to a 7-position of deaza-adenine or deaza-guanine.
- The labels contemplated in the present invention may be detected by many methods. For example, radiolabels may be detected using photographic film or scintillation counters, fluorescent markers may be detected using a photodetector to detect emitted light. Enzymatic labels are typically detected by providing the enzyme with a substrate and detecting, the reaction product produced by the action of the enzyme on the substrate, and calorimetric labels are detected by simply visualizing the colored label.
- The term “luminescence” and/or “fluorescence”, as used herein, refers to any process of emitting electromagnetic radiation (light) from an object, chemical and/or compound. Luminescence and/or fluorescence results from a system which is “relaxing” from an excited state to a lower state with a corresponding release of energy in the form of a photon. These states can be electronic, vibronic, rotational, or any combination of the three. The transition responsible for luminescence can be stimulated through the release of energy stored in the system chemically or added to the system from an external source. The external source of energy can be of a variety of types including, but not limited to, chemical, thermal, electrical, magnetic, electromagnetic, physical or any other type capable of causing a system to be excited into a state higher than the ground state. For example, a system can be excited by absorbing a photon of light, by being placed in an electrical field, or through a chemical oxidation-reduction reaction. The energy of the photons emitted during luminescence can be in a range from low-energy microwave radiation to high-energy x-ray radiation. Typically, luminescence refers to photons in the range from UV to IR radiation.
- The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
-
FIG. 1 presents exemplary data showing a comparison of sequencing performance for runs containing gallic acid (addG) in Cleave solution vs Baseline runs. Sequencing parameters include average error rate, average percentage of perfect (error free) reads, phasing parameters (lead and lag). -
FIG. 2 presents exemplary data showing a comparison of sequencing performance for runs containing gallic acid (addG) in Cleave solution vs Baseline runs. Sequencing included assessment of called variants (true positives—TP, false positives—FP). -
FIG. 3 presents exemplary data showing a comparison of sequencing performance for runs containing gallic acid (addG) in Cleave solution vs Baseline runs. Sequencing included assessment of average error rate per cycle. -
FIG. 4 presents exemplary data showing a comparison of sequencing performance for runs containing gallic acid (addG) in Cleave solution vs Baseline runs. Sequencing included assessment of the following performance indicators: average error rate per cycle, average percentage of perfect reads, percent of signal retention, false positive rate and lead/lag. Values higher than 0.95 on the third bar indicate statistical significance, first bar corresponds to baseline, second to experiment with relative improvement factor. -
FIG. 5 presents exemplary data showing an LC-MS analysis of a cleaved spacer arm terminating with free SH group and exposure to Cleave without additives. Formation of alkene moiety detected as a result of side reactions during cleavage step. -
FIG. 6 presents exemplary data showing a comparison of sequencing performance for runs containing gallic acid (addG) in Cleave solution vs solutions with gallic acid and Tween detergent. Sequencing included assessment of the following performance indicators: average error rate per cycle, average percentage of perfect reads, percent of signal retention, false positive rate and lead/lag. Values higher than 0.95 on the third bar indicate statistical significance, first bar corresponds to baseline, second to experiment with relative improvement factor -
FIG. 7 presents exemplary data showing a comparison of sequencing performance for runs containing addG alternatives in Cleave solution (pyrogallol, pyrocatechol, gentisic acid) vs baseline runs without any additive. Results are provided for two sample types (Clones and Gene Panel). Improvements are noted for sequencing KPIs such as error rate, percent perfect and lead/lag when addG alternatives such as pyrogallol, pyrocatechol, gentisic acid are added to Cleave. -
FIG. 8 presents representative electropherograms of sequencing products after sequencing under baseline conditions (A) and with gallic acid additive in Cleave (B). Higher yield of full length product observed in case with additive (B). -
FIG. 9 presents exemplary RP-HPLC cleavage studies of labeled dCTP nucleotide in the absence (baseline) and presence of additive (examples of gallic and gentisic acid). Byproducts are clearly visible in baseline and absent in chromatograms with additives. -
FIG. 10 presents exemplary data showing a comparison of sequencing performance for runs containing baseline imaging buffer vs imaging buffer containing additives: GR 5.10: Replace baseline Imaging buffer with a single HEPES pH 7.5 buffer with Gentisic acid at final concentration of 25 mM; GR 5.4: Add Gentisic acid (25 mM) to Image B; GR 5.5: Image B buffer with Trolox removed and Gentisic acid added (25 mM). -
FIG. 11 presents exemplary data showing the relative bead loss in flow cells during runs comparing indole-3-propionic acid (IPA: AddC_15FC) and gallic acid (GA: AddG_7FC). -
FIG. 12 presents exemplary data comparing the raw error rate for ascorbic acid (Add AA), additive C (Add C), additive G (light) along with an additive-free control (No add) where the results were generated in a sequencing run using the NA12878/101X gene panel as template. The raw error rate for ascorbic acid is significantly better than i) the no additive run, and ii) the run with additive C (while performing comparably to additive G). - The invention relates to methods, compositions, devices, systems and kits as described including, without limitation, reagents and mixtures for determining the identity of nucleic acids in nucleotide sequences using, for example, sequencing by synthesis methods. In particular, the present invention contemplates the use of polyphenolic compounds, known as antioxidant additives, to improve the efficiency of Sequencing-By-Synthesis reactions. For example, gallic acid (GA) is shown herein to be one of many exemplary SBS polyphenolic additives.
- One step in the sequencing-by-synthesis workflow is the removal of the fluorescent label which is covalently attached via a cleavable linker molecule to the ring-position of the heterocyclic base of the nucleotide (reversible terminator) involved in the incorporation step. The efficacy of the cleave step is reflected not only in the efficiency of the fluorescent label cleavage but also in the mitigation of reaction by-products that could accumulate in the flow cell and interfere with subsequent base incorporation step. Examples of such compounds are radical by-products that may form due to radical pathways involved in the omolytic scission of the linker molecule to release the fluorescent label and excess cleave reagent (i. e., tris(2-carboxyethyl)phosphine or TCEP). These may build up in the flow cell and carry over into the subsequent base extension step thus causing premature de-protection of the 3'-OH moiety and causing more than one base to incorporate. An effective cleave step is important for single nucleotide incorporation throughout the sequencing reaction, as well as a prerequisite for low error rate and long read length. To improve the efficacy of the cleave step, molecules that quench radical pathways and oxidize excess TCEP are contemplated, such as ascorbic acid, so as to enhance the efficacy of this reactive step.
- In one embodiment, the present invention contemplates a series of method steps performed by an automated sequencing by synthesis instrument. See U.S. Pat. No. 9,145,589, hereby incorporated by reference. In one embodiment, the instrument is comprised of numerous reagent reservoirs. Each reagent reservoir has a specific reactivity reagent dispensed within the reservoir to support the SBS process, for example:
- One reactive step in a method for sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators comprises cleaving a fluorescent label from a nucleotide analogue molecule. It is not intended that the present invention be limited by the nature of the cleaving agent.
- In one embodiment, the SBS method comprises doing different steps at different stations. By way of example, each station is associated with a particular step. While not limited to particular formulations, some examples for these steps and the associated reagents are shown below:
- 1) Extend A Reagent: Comprises reversibly terminated labeled nucleotides and polymerase.
- The composition of Extend A is as follows:
-
Component Conc PNSE (% wt/vol) 0.005% Tris x HCl (pH 8.8), mM 50 NaCl (mM) 50 EDTA (mM) 1 MgSO4 (mM) 10 Cystamine (mM) 1 Glycerol (% wt/vol) 0.01% Therminator IX* (U/ml) 10 N3-dCTP (μM) 3.83 N3-dTTP (μM) 3.61 N3-dATP (μM) 4.03 N3-dGTP (μM) 0.4 Alexa488-dCTP (nM) 550 R6G-dUTP (nM) 35 ROX-dATP (nM) 221 Cy5-dGTP (nM) 66 *with Alkylated free Cysteine - 2) Extend B Reagent: Comprises reversibly terminated unlabeled nucleotides and polymerase, but lacks labeled nucleotide analogues. The composition of Extend B is as follows:
-
Component Conc PNSE (% wt/vol) 0.005% Tris x HCl (pH 8.8), mM 50 NaCl (mM) 50 EDTA (mM) 1 MgSO4 (mM) 10 Glycerol (% wt/vol) 0.01% Therminator IX* (U/ml) 10 N3-dCTP (μM) 21 N3-dTTP (μM) 17 N3-dATP (μM) 21 N3-dGTP (μM) 2 *Alkylated free Cysteine - 3)
Wash solution 1 with a detergent (e.g., polysorbate 20) citrate buffer (e.g., saline) - 4) Cleave Reagent: A cleaving solution composition is as follows:
-
Component Conc NaOH (mM) 237.5 TrisHCl (pH 8.0) (mM) 237.5 TCEP (mM) 50 - 5)
Wash solution 2 with a detergent (e.g., polysorbate 20) a tris(hydroxymethyl)-aminomethane (Tris) buffer. - In one embodiment, the present invention contemplates compositions and compounds that are polyphenolic compounds as antioxidant additives which improve methods of sequencing by synthesis. In one embodiment, the polyphenolic compound includes, but is not limited to, gallic acid, gentisic acid, pryocatechol, pyrogallol, hydroquinone, and/or resorcinol.
- One embodiment of the invention includes addition of polyphenolic additives in sequencing reactions of Cleavage solution to improve lifetime of solution, to reduce undesirable free radical driven side reactions, allow premixing, and as a result improve sequencing performance. Another embodiment includes addition of polyphenolic compounds to Imaging solution to improve lifetime of solution and to reduce undesirable free radical driven side reactions.
- Yet another embodiment of the invention is addition of polyphenolic compounds to Extend solution to improve lifetime of solution and to reduce undesirable free radical driven side reactions. In one embodiment of the invention the polyphenolic compounds are antioxidants. In yet another embodiment the polyphenolic compounds have free radical scavenging properties.
- Current sequencing processes includes a Cleave solution with buffered phosphine to deprotect 3'-OH groups and disulfide dye linker. This solution has limited activity window due to oxygen absorption from the air and open Cleave container on GeneReader instrument. Literature reports indicate that phosphines such as TCEP (Tris(carboxyethyl)phosphine) can lead to by-products with thiol-based compounds. One example is conversion of cysteine to dehydroalanine residues in peptides. The process is thought to involve a free radical path. Zhouxi et al., Rapid Commun Mass Spectrom. (2010) 24(3):267-275. Analysis of SBS nucleotides cleavage reactions in solution by means of LC-MS indicates formation of additional species in addition to expected products. Analysis of sequencing products by means of denaturing capillary electrophoresis indicates presence of non-full length products.
- One Imaging solution currently used on GeneReader uses an active oxygen scavenging system and radical/triplet state scavenger. Extend A/B solutions do not contain reducing agents due to compatibility with sequencing chemistry (disufide bridges). In another embodiment, polyphenolic anti-oxidant compounds are identified that actively scavenge dissolved oxygen out of a Cleave solution and prolong useful life time of a Cleave solution and increase its efficiency. In another embodiment, improved performance of a Cleave step and reduction of side reactions is disclosed.
- Preliminary data included tests with polyphenolic additives to a Cleave reagent to assess improvements SBS performance. The results suggested that several polyphenolic compounds had a high antioxidant potential. For example, two promising polyphenolic compounds were chosen for further studies: gallic acid and gentisic acid. In addition to reducing available oxygen and having positive impact on the lifetime of a Cleave solution (reducing agent) these two polyphenolic compounds had additional positive impact on sequencing performance possibly due to reducing side reactions.
- Sequencing SBS chemistry performance was assessed using standard baseline SBS conditions (50 mM TCEP at pH=8.5) versus runs with additives at the same pH. To this effect, the following conclusions were made based on experimental data and described further in detail:
-
- 1. Analysis of cleavage reactions at nucleotide level by means of analytical HPLC and LC-MS (labeled and terminating nucleotide) in the absence and presence of additives was performed. These analyses revealed that cleavage reactions containing antioxidant compounds (50 mM) including, but not limited to, gallic acid, gentisic acid, pyrocatechol or pyrogallol revealed fewer side products.
- 2. Sequencing runs containing Cleave solution with phosphine only or containing gallic acid, gentisic acid, pyrocatechol, pyrogallol were conducted at varying concentrations. Analysis of sequencing KPIs indicates better performance as indicated by lower error rate, higher signal margin and lower lead values as well as lower false positive rate for variants effectively extending usable read length by 25-50%. Analysis by CE reveals higher yield of full length sequencing products. Flowcell data homegeneity was also improved indicating possibly beneficial impact on Cleave solution clearance from the flowcell.
- 3. Sequencing runs containing gallic acid, gentisic acid, pyrocatechol, or pyrogallol in Imaging solution indicated better performance as shown by lower error rate, higher signal margin and lower lead values as well as lower false positive rate for variants. Analysis by CE reveals higher yield of full length sequencing products.
- 4. Identification of additional compounds with similar properties were identified. Additional compounds evalauted as Cleave additives showed similar benefits as demonstrated in 1-3 above. These compounds contain poly-phenolic groups or have antioxidant properties. Compounds tested include pyrogallol, pyrocatechol, hydroquinone, resorcinol, but it is not intended that the invention is limited to this set of compounds.
- A. Gallic Acid
- Gallic acid (GA) has been shown to improve sequencing performance and allow the system to provide a filtered trimmed sequence output of 1 Gb.
- Gallic acid is found in a number of land plants, such as the parasitic plant, Cynomorium coccineum, the aquatic plant, Myriophyllum spicatum, and the blue-green alga, Microcystis aeruginosa. Zucca et al., “Evaluation of Antioxidant Potential of “Maltese Mushroom” (Cynomorium coccineum) by Means of Multiple Chemical and Biological Assays” Nutrients 5(1):149-161; and Nakai, S (2000). “Myriophyllum spicatum-released allelopathic polyphenols inhibiting growth of blue-green algae Microcystis aeruginosa” Water Research 34(11):3026-3032. Gallic acid is a trihydroxybenzoic acid, a type of phenolic acid, a type of organic acid, also known as 3,4,5-trihydroxybenzoic acid, found in gallnuts, sumac, witch hazel, tea leaves, oak bark, and other plants. The chemical formula is C6H2(OH)3COOH, having the following structure:
- Gallic acid is found both free and as part of hydrolyzable tannins. The gallic acid groups are usually bonded to form dimers such as ellagic acid. Hydrolysable tannins break down on hydrolysis to give gallic acid and glucose or ellagic acid and glucose, known as gallotannins and ellagitannins respectively. Gallic acid may also form intermolecular esters (depsides) such as digallic and trigallic acid, and cyclic ether-esters (depsidones) and is commonly used in the pharmaceutical industry. Fiuza et al., “Phenolic acid derivatives with potential anticancer properties—a structure—activity relationship study. Part 1: Methyl, propyl and octyl esters of caffeic and gallic acids”. Bioorganic & Medicinal Chemistry (Elsevier) 12 (13): 3581-3589. Gallic acid is easily freed from gallotannins by acidic or alkaline hydrolysis. When gallic acid is heated with concentrated sulfuric acid, rufigallol is produced by condensation. Oxidation with arsenic acid, permanganate, persulfate, or iodine yields ellagic acid, as does reaction of methyl gallate with iron(III) chloride.
- Gallic acid is formed from 3-dehydroshikimate by the action of the enzyme shikimate dehydrogenase to produce 3,5-didehydroshikimate. This latter compound tautomerizes to form the redox equivalent gallic acid, where the equilibrium lies essentially entirely toward gallic acid because of the coincidentally occurring aromatization. Dewick et al., (1969) “Phenol biosynthesis in higher plants. Gallic acid”. Biochemical Journal 113 (3): 537-542. Gallate dioxygenase and gallate decarboxylase are enzymes responsible for the degradation of gallic acid.
- The data presented herein demonstrate that SBS runs with gallic acid showed no bead loss as shown by its comparison to SBS runs using indole-3-propionic acid (IPA). See,
FIG. 11 . These data show that gallic acid, like IPA, does not undergo any bead loss during SBS, contradicting previous reports. Although it is not necessary to understand the mechanism of an invention, it is believed that when a certain pH value is reached, Gallic acid undergoes an irreversible transition to a new chemical entity. It is believed that this chemical transition generates an active gallic acid derivative that is responsible for previously observed bead loss. In one embodiment, the present invention contemplates an SBS reagent (e.g., for example, aCleave 1 buffer, where gallic acid is not mixed in the absence of TCEP. When gallic acid and TCEP are both present in the SBS reagent, no bead loss is observed. - This lack of bead loss is reflected in data showing improved error rates when SBS runs were compared between the presence of gallic acid, IPA and ascorbic acid. All three additives improved SBS error rates when compared to no additive. See,
FIG. 12 . The data show that gallic acid (AddG) results in a raw error rate that is significantly better than no additive and IPA (AddC). - B. Gentisic Acid
- Gentisic acid is a dihydroxybenzoic acid. It is a derivative of benzoic acid and a minor (1%) product of the metabolic break down of aspirin. It is also found in the African tree Alchornea cordifolia and in wine.
- Gentisic acid may be produced by carboxylation of hydroquinone:
-
C6H4(OH)2+CO2→C6H3(CO2H)(OH)2 - This conversion is an example of a Kolbe-Schmitt reaction and results in the following structure:
- Alternatively the compound can be synthesized from Salicylic acid via Elbs persulfate oxidation (50% yield). Schock Jr. et al., (1951) “The Persulfate Oxidation of Salicylic Acid. 2,3,5-Trihydroxybenzoic Acid” The Journal of Organic Chemistry 16(11):1772-1775. As a hydroquinone, gentisic acid is readily oxidized and is used as an antioxidant excipient in some pharmaceutical preparations. In the laboratory, it is used as a sample matrix in matrix-assisted laser desorption/ionization (MALDI) mass spectrometry, and has been shown to conveniently detect peptides incorporating the boronic acid moiety by MALDI. Strupat et al., (1991) “2,5-Dihidroxybenzoic acid: a new matrix for laser desorption-ionization mass spectrometry” Int. J. Mass Spectrom. Ion Processes 72(111):89-102; and Crumpton et al., (2011) “Facile Analysis and Sequencing of Linear and Branched Peptide Boronic Acids by MALDI Mass Spectrometry” Analytical Chemistry 83(9):3548-3554.
- C. Pryocatechol
- Pyrocatechol, also known as catechol or 1,2-dihydroxybenzene, is an organic compound with the molecular formula C6H4(OH)2. It is the ortho isomer of the three isomeric benzenediols. This colorless compound occurs naturally in trace amounts. It was first discovered by destructive distillation of the plant extract catechin. About 20 million kg are now synthetically produced annually as a commodity organic chemical, mainly as a precursor to pesticides, flavors, and fragrances.
- Catechol is produced industrially by the hydroxylation of phenol using hydrogen peroxide:
-
C6H5OH+H2O2→C6H4(OH)2+H2O - and results in the following structure:
- Previously, it was produced by hydrolysis of 2-substituted phenols, especially 2-chlorophenol, with hot aqueous solutions containing alkali metal hydroxides. Its methyl ether derivative, guaiacol, converts to catechol via hydrolysis of the CH3-O bond as promoted by hydriodic acid.
- D. Pyrogallol
- Pyrogallol is an organic compound with the formula C6H3(OH)3 having the following chemical structure:
- It is a white solid although because of its sensitivity toward oxygen, samples are typically brownish. It is one of three isomeric benzenetriols. It is produced by heating gallic acid that results in decarboxylation. An alternate preparation involves treating para-chlorophenoldisulphonic acid with potassium hydroxide.
- E. Hydroquinone
- Hydroquinone, also benzene-1,4-diol or quinol, is an aromatic organic compound that is a type of phenol, a derivative of benzene, having the chemical formula C6H4(OH)2, having the following structure:
- Its chemical structure features two hydroxyl groups bonded to a benzene ring in a para position. It is a white granular solid. Substituted derivatives of this parent compound are also referred to as hydroquinones.
- The reactivity of hydroquinone's O—H groups resembles other phenols, being weakly acidic. The resulting conjugate base undergoes easy O-alkylation to give mono- and diethers. Similarly, hydroquinone is highly susceptible to ring substitution by Friedel-Crafts reactions such as alkylation. This reaction is exploited en route to popular antioxidants such as 2-tert-butyl-4-methoxyphenol (“BHA”). The useful dye quinizarin is produced by diacylation of hydroquinone with phthalic anhydride. Hydroquinone undergoes oxidation under mild conditions to give benzoquinone. This process can be reversed. Some naturally occurring hydroquinone derivatives exhibit this sort of reactivity, one example being coenzyme Q. Industrially this reaction is exploited both with hydroquinone itself but more often with its derivatives where one OH has been replaced by an amine.
- There are various other uses associated with its reducing power. As a polymerization inhibitor, hydroquinone prevents polymerization of acrylic acid, methyl methacrylate, cyanoacrylate, and other monomers that are susceptible to radical-initiated polymerization. This application exploits the antioxidant properties of hydroquinone.
- Hydroquinone can undergo mild oxidation to convert to the compound parabenzoquinone, C6H4O2, often called p-quinone or simply quinone. Reduction of quinone reverses this reaction back to hydroquinone. Some biochemical compounds in nature have this sort of hydroquinone or quinone section in their structures, such as Coenzyme Q, and can undergo similar redox interconversions.
- Hydroquinone can lose an H+ from both to form a diphenolate ion. The disodium diphenolate salt of hydroquinone is used as an alternating comonomer unit in the production of the polymer PEEK.
- F. Resorcinol
- Resorcinal is the 1,3-isomer (or meta-isomer) of benzenediol with the formula C6H4(OH)2, having the following structure:
- Resorcinol crystallizes from benzene as colorless needles that are readily soluble in water, alcohol, and ether, but insoluble in chloroform and carbon disulfide. Sodium amalgam reduces it to dihydroresorcin, which when heated to 150 to 160° C. with concentrated barium hydroxide solution gives γ-acetylbutyric acid and when fused with potassium hydroxide, resorcinol yields phloroglucin, pyrocatechol, and diresorcin.
- In one embodiment, the present invention contemplates a SBS method comprising the steps shown in Table 1. See Olejink et al., “Methods And Compositions For Inhibiting Undesired Cleaving Of Labels” U.S. Pat. No. 8,623,598 (herein incorporated by reference in its entirety).
-
TABLE 1 An Exemplary SBS Workflow Fluid Movements Volume Speed Station Temp Time Step Reagent mL mL/s Number ° C. [s] 1. Dispense Reagent Reagent 1 100 67 3 65 7 2. Incubate Reagent Reagent 1 n/a n/a 3 65 210 3. Dispense Reagent Reagent 2 100 67 4 65 7 4. Incubate Reagent Reagent 2 n/a n/a 4 65 210 5. Dispense Reagent Reagent 3 330 27 5 Ambient 12 6. Dispense Reagent Reagent 200 27 5 Ambient 15 4 + 5 7. Image n/a n/a n/a 11 Ambient 210 8. Dispense Reagent Reagent 3 330 27 20 65 12 9. Dispense Reagent Reagent 6 100 67 1 65 7 10. Incubate Reagent Reagent 6 n/a n/a 1 65 210 11. Incubate Reagent Reagent 6 n/a n/a 2 65 210 12. Dispense Reagent Reagent 7 990 27 2 65 37 13. Go to Step 1 Reagent 1 = Extend A;Reagent 2 = Extend B;Reagent 3 = Wash;Reagent 4 = Image A; Reagent 5 = Image B;Reagent 6 = Cleave; and Reagent 7 = Wash 11 - All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in the art and in fields related thereto are intended to be within the scope of the following claims.
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/386,883 US20210355529A1 (en) | 2016-02-11 | 2021-07-28 | Polyphenolic additives in sequencing-by-synthesis |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662293969P | 2016-02-11 | 2016-02-11 | |
US201662419685P | 2016-11-09 | 2016-11-09 | |
US15/427,664 US10337050B2 (en) | 2016-02-11 | 2017-02-08 | Polyphenolic additives in sequencing by synthesis |
US16/422,056 US11078526B2 (en) | 2016-02-11 | 2019-05-24 | Polyphenolic additives in sequencing by synthesis |
US17/386,883 US20210355529A1 (en) | 2016-02-11 | 2021-07-28 | Polyphenolic additives in sequencing-by-synthesis |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/422,056 Continuation US11078526B2 (en) | 2016-02-11 | 2019-05-24 | Polyphenolic additives in sequencing by synthesis |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210355529A1 true US20210355529A1 (en) | 2021-11-18 |
Family
ID=59561276
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/427,664 Active 2037-04-11 US10337050B2 (en) | 2016-02-11 | 2017-02-08 | Polyphenolic additives in sequencing by synthesis |
US16/422,056 Active 2037-05-26 US11078526B2 (en) | 2016-02-11 | 2019-05-24 | Polyphenolic additives in sequencing by synthesis |
US17/386,883 Pending US20210355529A1 (en) | 2016-02-11 | 2021-07-28 | Polyphenolic additives in sequencing-by-synthesis |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/427,664 Active 2037-04-11 US10337050B2 (en) | 2016-02-11 | 2017-02-08 | Polyphenolic additives in sequencing by synthesis |
US16/422,056 Active 2037-05-26 US11078526B2 (en) | 2016-02-11 | 2019-05-24 | Polyphenolic additives in sequencing by synthesis |
Country Status (4)
Country | Link |
---|---|
US (3) | US10337050B2 (en) |
EP (1) | EP3414338B1 (en) |
CN (1) | CN109196113B (en) |
WO (1) | WO2017139419A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3527673A1 (en) | 2018-02-15 | 2019-08-21 | QIAGEN GmbH | Sequencing method |
EP3702474A1 (en) | 2019-02-26 | 2020-09-02 | QIAGEN GmbH | Sequencing method and kit |
CN113795595B (en) * | 2020-04-20 | 2023-02-28 | 深圳华大智造科技股份有限公司 | DNA protective agents in DNA imaging buffers |
WO2024050820A1 (en) * | 2022-09-09 | 2024-03-14 | 深圳华大智造科技股份有限公司 | Antioxidant composition and use thereof in nucleic acid detection |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5116734A (en) * | 1989-09-01 | 1992-05-26 | Digene Diagnostics, Inc. | Highly sensitive method for detecting peroxidase |
US6187286B1 (en) * | 1996-12-27 | 2001-02-13 | The General Hospital Corporation | Tumor imaging agents, methods and kits |
JP2004210741A (en) * | 2003-01-08 | 2004-07-29 | B Road:Kk | Composition for allergen neutralization |
US20100323350A1 (en) * | 2007-02-05 | 2010-12-23 | Intelligent Biosystems, Inc. | Methods And Devices For Sequencing Nucleic Acids In Smaller Batches |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
JP2002515889A (en) * | 1996-10-28 | 2002-05-28 | ニユコメド・イメージング・アクシエセルカペト | Improved diagnostic / therapeutic agents |
JP2001524808A (en) * | 1996-12-10 | 2001-12-04 | ジーントレイス・システムズ・インコーポレイテッド | Releasable non-volatile mass labeling molecules |
AU5620600A (en) * | 1999-06-16 | 2001-01-02 | University Of Cincinnati, The | Agent and process for isolation of extra-chromosomal nucleic acids |
EP3034627B1 (en) | 2000-10-06 | 2019-01-30 | The Trustees of Columbia University in the City of New York | Massive parallel method for decoding dna and rna |
US20080026380A1 (en) * | 2006-07-31 | 2008-01-31 | Siddiqi Suhaib M | Nucleotide analogs |
JP2008182221A (en) * | 2006-12-28 | 2008-08-07 | Sanyo Chem Ind Ltd | Cleaning agent for semiconductor substrate |
US8017338B2 (en) * | 2007-11-20 | 2011-09-13 | Life Technologies Corporation | Reversible di-nucleotide terminator sequencing |
WO2009078123A1 (en) * | 2007-12-17 | 2009-06-25 | Sanyo Chemical Industries, Ltd. | Cleaning agent and cleaning method for electronic material |
US8623598B2 (en) | 2008-03-19 | 2014-01-07 | Intelligent Bio Systems, Inc. | Methods and compositions for inhibiting undesired cleaving of labels |
US20140193386A1 (en) * | 2008-06-18 | 2014-07-10 | Lifebond Ltd. | Method for enzymatic cross-linking of a protein |
WO2010059880A2 (en) * | 2008-11-19 | 2010-05-27 | Pacific Biosciences Of California, Inc. | Photo-induced damage mitigating agents and preparation and methods of use thereof |
TWI403556B (en) * | 2010-02-12 | 2013-08-01 | Elite Material Co Ltd | A resin composition, and a prepreg, a laminate, and a circuit board comprising the resin composition |
US9115353B2 (en) * | 2011-01-31 | 2015-08-25 | Illumina, Inc. | Method for nucleotide detection |
-
2017
- 2017-02-08 CN CN201780018264.1A patent/CN109196113B/en active Active
- 2017-02-08 US US15/427,664 patent/US10337050B2/en active Active
- 2017-02-08 EP EP17750729.0A patent/EP3414338B1/en active Active
- 2017-02-08 WO PCT/US2017/017068 patent/WO2017139419A1/en active Application Filing
-
2019
- 2019-05-24 US US16/422,056 patent/US11078526B2/en active Active
-
2021
- 2021-07-28 US US17/386,883 patent/US20210355529A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5116734A (en) * | 1989-09-01 | 1992-05-26 | Digene Diagnostics, Inc. | Highly sensitive method for detecting peroxidase |
US6187286B1 (en) * | 1996-12-27 | 2001-02-13 | The General Hospital Corporation | Tumor imaging agents, methods and kits |
JP2004210741A (en) * | 2003-01-08 | 2004-07-29 | B Road:Kk | Composition for allergen neutralization |
US20100323350A1 (en) * | 2007-02-05 | 2010-12-23 | Intelligent Biosystems, Inc. | Methods And Devices For Sequencing Nucleic Acids In Smaller Batches |
Non-Patent Citations (1)
Title |
---|
Translation of JP2004-210741, pp. 1-12 (Year: 2004) * |
Also Published As
Publication number | Publication date |
---|---|
EP3414338A1 (en) | 2018-12-19 |
EP3414338A4 (en) | 2019-07-24 |
CN109196113A (en) | 2019-01-11 |
US20190330690A1 (en) | 2019-10-31 |
US20170233796A1 (en) | 2017-08-17 |
US11078526B2 (en) | 2021-08-03 |
CN109196113B (en) | 2022-10-04 |
WO2017139419A1 (en) | 2017-08-17 |
US10337050B2 (en) | 2019-07-02 |
EP3414338B1 (en) | 2022-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210355529A1 (en) | Polyphenolic additives in sequencing-by-synthesis | |
EP3538093B1 (en) | Photoprotective mixtures as imaging reagents in sequencing-by-synthesis | |
JP5902843B2 (en) | Single nucleotide polymorphisms for determining allele-specific expression of IGF2 gene and combinations of new and known polymorphisms | |
US20180305684A1 (en) | Scavenger Compounds for Improved Sequencing-by-Synthesis | |
CN108414488B (en) | Specific fluorescent probe, method and kit for detecting copper ions | |
US20120225428A1 (en) | Type of universal probe for the detection of genomic variants | |
US20120052482A1 (en) | Kit for detecting hepatitis c virus and method of detecting hepatitis c virus using the same | |
JP2009213445A (en) | Method for detecting nucleic acid having target nucleotide sequence, probe set and method for identifying nucleic acid | |
Tang et al. | A single quantum dot-based biosensor for DNA point mutation assay | |
US20170306155A1 (en) | Merocyanine-based compounds, and dyes, kits and contrast medium compositions for labelling biomolecules comprising the same | |
US20050250134A1 (en) | Fluorescent energy transfer labeled nucleic acid substrates and methods of use thereof | |
US20180148781A1 (en) | Antioxidant Compounds For Cleave Formulations That Support Long Reads In Sequencing-By-Synthesis | |
WO2009096429A1 (en) | Method for extraction of nucleotide | |
KR101521381B1 (en) | Method and kit for diagnosing early mortality syndrome of shrimps using real-time PCR | |
JP5200001B2 (en) | A novel detection probe that works by molecular recognition | |
KR102142137B1 (en) | Primers for differentiation between Rabies virus and vaccine strains and differentiating method between Rabies virus and vaccine strains using the same | |
CN101983245B (en) | Kit and method for determining whether or not unmethylated cytosine conversion treatment is appropriately performed and method for analyzing methylated DNA using the same | |
US20180127819A1 (en) | Enhancing Sequencing Performance in Sequencing-by-Synthesis | |
Trévisiol et al. | Synthesis and Biological Evaluation of Nucleoside Triphosphates Incorporating an Oxyamino Function for “Post-amplification Labelling” | |
GB2405471A (en) | Methods for determining the activity of enzymes which alter the structures of nucleic acids using chemiluminescence quenching | |
Lehmusvuori | Switchable lanthanide fluorescence probes in homogenous molecular diagnostics | |
Probst | Development and evaluation of multiplex and high-throughput SNP analysis for the ABCA1 gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING |
|
AS | Assignment |
Owner name: QIAGEN SCIENCES, LLC, MARYLAND Free format text: MERGER;ASSIGNOR:QIAGEN WALTHAM, INC.;REEL/FRAME:057043/0685 Effective date: 20171231 Owner name: ISOPLEXIS CORPORATION, CONNECTICUT Free format text: PATENT PURCHASE AGREEMENT;ASSIGNOR:QIAGEN SCIENCES, LLC;REEL/FRAME:057039/0300 Effective date: 20210512 Owner name: QIAGEN WALTHAM, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:OLEJNIK, JERZY;PERBOST, MICHEL GEORGES;SIGNING DATES FROM 20171205 TO 20180510;REEL/FRAME:057031/0190 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |